PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Duloxetine - Pain (Neuropathic)

PAD Profile : Duloxetine - Pain (Neuropathic) Important

Keywords :
neuropathic pain, diabetic neuropathy, postherpetic neuralgia, PHN
Brand Names Include :
Cymbalta
Important Information :
Licensed only for diabetic peripheral neuropathic pain but also recommended as per NICE CG173 (off- label indication) as a treatment option in neuropathic pain.

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Capsules
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 October 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Duloxetine 60mg once daily or amitriptyline are recommended as treatment options at step 1 of the local neuropathic pain guidelines..
Duloxetine is licensed only for diabetic peripheral neuropathic pain but is also recommended by NICE as a treatment option in neuropathic pain.
See guidelines below.

03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Duloxetine has been considered by the PCN and has been assigned a GREEN traffic light status NOTE - the branded product, Cymbalta, was considered BLACK at the PCN in May 2017.

Associated BNF Codes

04. Central Nervous System
04.07.03. Neuropathic pain
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More